Keros Therapeutics(KROS)
搜索文档
Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-11-07 05:01
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended September 30, 2024. “This continues to be ...
Keros Therapeutics to Present at the Guggenheim Healthcare Innovation Conference
GlobeNewswire News Room· 2024-11-06 21:00
LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”), today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the G ...
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
GlobeNewswire News Room· 2024-08-28 20:00
LEXINGTON, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will present at the following healthcare ...
Keros Therapeutics(KROS) - 2024 Q2 - Quarterly Report
2024-08-08 04:04
产品管线 - 公司正在开发三款产品候选药物:elritercept、cibotercept和KER-065[83] - elritercept正在进行II期临床试验,用于治疗骨髓异常增生综合征和骨髓纤维化相关的血细胞减少症[83] - cibotercept正在进行II期临床试验,用于治疗肺动脉高血压[83] - KER-065正在进行I期临床试验,用于治疗肥胖和神经肌肉疾病[83] 融资情况 - 公司于2024年1月完成了一次公开发行,募集资金约1.511亿美元[86] - 公司于2021年5月和2024年6月分别建立了总额为4亿美元的"随时发行"股票融资计划[84,85] - 截至2024年6月30日,公司现金及现金等价物为4.059亿美元[87] 许可协议 - 公司在2016年与麻省总医院签订了一项独家专利许可协议,获得了相关技术的许可权[90] - 公司与Hansoh (Shanghai) Healthtech Co., Ltd.签订独家许可协议,授予其在中国大陆、香港和澳门地区开发、生产和商业化elritercept及其相关产品的权利[91] - 根据协议,公司将获得1800万美元的首付款,并有机会获得最高2.705亿美元的里程碑付款和销售提成[91] - 公司将与Hansoh签订制造技术转让协议,转让制造所需的全部文件和信息,Hansoh需支付相关技术转让服务费用[92] 收入来源 - 公司目前尚未产生任何产品销售收入,收入主要来自研究合作和知识产权许可[93] 费用情况 - 研发费用主要包括临床试验、制造、人员、设施等方面的支出,预计未来会随着管线的推进而持续增加[95][103][107] - 一般及行政费用主要包括人员、专业服务费用等,随着公司规模扩大而增加[96][104] - 2024年上半年研发费用较2023年同期增加1.51亿美元,主要由于KER-065、cibotercept等项目的临床和制造支出增加以及人员费用上升[107][108][109] - 2024年上半年一般及行政费用较2023年同期增加约120万美元,主要由于人员和专业服务费用增加[104] - 一般及行政费用同比增加约370万美元,主要由于(i)人员费用增加250万美元,其中包括额外的160万美元股票激励成本,以支持公司的组织增长和实现公司目标;以及(ii)专业费用、设施、供应品和其他费用净增加170万美元,以支持业务增长,部分被董事和高管保险费用减少50万美元所抵消[110] 其他收益 - 其他收益主要来自于现金等的投资收益[98][104] - 其他收入净额同比增加约370万美元,主要由于股息收入增加410万美元,部分被其他费用净额增加40万美元所抵消[111] 财务状况 - 公司自成立以来一直亏损,截至2024年6月30日和2023年12月31日的累计亏损分别为4.698亿美元和3.814亿美元[112] - 公司预计未来12个月内现有现金和现金等价物将足以满足预期的流动性需求[113] - 2024年上半年经营活动使用现金8436万美元,主要由于净亏损8840万美元和经营资产负债变动使用现金1410万美元,部分被非现金费用如股份支付1690万美元等抵消[116] - 2024年上半年筹资活动提供现金16033万美元,主要包括(i)公开发行普通股净募集15110万美元;(ii)ATM计划下发行普通股净募集60万美元;以及(iii)行权期权收到870万美元[119] 风险因素 - 公司面临着通胀、利率上升和经济衰退风险,可能会对公司的运营成本和财务状况产生不利影响[89] - 公司现金和现金等价物投资于保本的货币市场基金和计息储蓄账户,预计利率变动不会对公司经营业绩和现金流产生重大影响[125] - 公司无可变利率债务,因此不存在利率风险[126] - 公司无重大合同义务和承诺变化[121]
Keros Therapeutics(KROS) - 2024 Q2 - Quarterly Results
2024-08-08 04:02
临床试验进展 - 公司在第二季度继续推进管线中所有项目的进展,包括elritercept(KER-050)项目的最新监管和数据更新[2] - 公司对cibotercept(KER-012)在肺动脉高压患者II期临床试验的强劲入组情况感到兴奋,并计划在今年第四季度完成该试验的入组[2] 财务情况 - 公司在第二季度的净亏损为4530万美元,较2023年同期增加780万美元,主要由于研发投入和支持公司临床及企业目标的投资增加[3] - 研发费用为4050万美元,较2023年同期增加800万美元,主要由于研发工作、生产活动和人员费用的增加以支持管线的推进[4] - 公司于2024年6月30日的现金及现金等价物为4.059亿美元,较2023年12月31日的3.311亿美元有所增加,预计可为公司运营和资本支出需求提供资金支持至2027年[6] 产品管线 - 公司正在开发三大产品候选药物:elritercept用于治疗血细胞减少症、cibotercept用于治疗肺动脉高压和心血管疾病、KER-065用于治疗肥胖和神经肌肉疾病[7]
Keros Therapeutics Reports Second Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-08-08 04:01
LEXINGTON, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today reported financial results for the quarter ended June 30, 2024. "Keros continued to build upon the progress of all progra ...
Keros Therapeutics Announces Leadership Updates
Newsfilter· 2024-06-18 04:01
Keros' Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1, 2024. Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain an active Board member. Jean-Jacques Bienaimé will serve as the Lead Independent Director of the Board, effective July 1, 2024. "I am honored to expand my role with Keros as the next Chair of its Board. I look forward to working with and leading our Board, which is comprised of directors with diverse ba ...
Keros Therapeutics Announces Leadership Updates
GlobeNewswire News Room· 2024-06-18 04:01
Keros' Board has appointed Jasbir S. Seehra, Ph.D., Chief Executive Officer, as Chair of the Board, effective July 1, 2024. Dr. Seehra will succeed current Chair Carl L. Gordon, Ph.D, C.F.A., who will remain an active Board member. Jean-Jacques Bienaimé will serve as the Lead Independent Director of the Board, effective July 1, 2024. "We're pleased to welcome Jas to the Board Chair position," said Dr. Gordon. "The Board and I have worked closely with and observed Jas in his role as director and as CEO. We b ...
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
GlobeNewswire News Room· 2024-06-17 18:00
Elritercept continued to demonstrate a durable transfusion independence in lower-risk myelodysplastic syndromes, including in patients with high transfusion burden Durable clinical responses were associated with improvements in patient-reported measures of fatigue Data from ongoing Phase 2 clinical trial in myelofibrosis continue to demonstrate that elritercept can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit, as supported by observed reduct ...
Keros Therapeutics Presents Clinical Data from its Elritercept (KER-050) Program at the 29th Annual Hybrid Congress of the European Hematology Association
Newsfilter· 2024-06-17 18:00
文章核心观点 - 公司的主要产品候选药物elritercept在治疗骨髓增生异常综合征(MDS)和骨髓纤维化(MF)相关贫血等血细胞减少症方面显示出良好的疗效和安全性[1][2][11][17] - elritercept可以改善MDS和MF患者的无输血依赖时间,并且能够改善患者的疲劳感等生活质量指标[5][6][9][10] - elritercept还可以减少MF患者的脾脏体积和症状评分,为MF患者带来更广泛的临床获益[15][16] 关于MDS的临床试验 - 在MDS临床试验中,55.6%的患者在24周内达到总体红细胞反应,包括无输血依赖和红细胞系血液学改善[5] - 在可评估的输血依赖患者中,41.3%在24周内实现了至少8周的无输血依赖,其中61.5%的患者在48周内维持了至少24周的无输血依赖[6] - 在高输血负荷患者中,34.8%在24周内实现了至少8周的无输血依赖,其中50%的患者在48周内维持了至少24周的无输血依赖[7] - 在基线EPO<500 U/L的患者中,50%在24周内实现了至少8周的无输血依赖,在高输血负荷且EPO<500 U/L的患者中,42.9%在24周内实现了至少8周的无输血依赖[8] - 获得无输血依赖反应的患者在生活质量(FACIT-Fatigue量表)方面获得了持续且临床意义上的改善[10] 关于MF的临床试验 - elritercept可以改善MF和ruxolitinib治疗相关的贫血,大多数无输血依赖患者在12周内血红蛋白水平有所提高[13] - 60.6%的高输血负荷患者在12周内输血量有所减少,其中60%的患者输血量减少50%以上[14] - 在3.0 mg/kg及以上剂量的elritercept联合ruxolitinib治疗组,72.7%的患者输血量减少50%以上,45.5%的患者实现了无输血依赖[14] - 52.9%的基线脾脏体积≥450 cm3的患者在24周时脾脏体积有所减小,包括3例减小35%以上[15] - 大多数基线症状评分较高的患者在24周时症状评分有所改善,包括3例症状评分减少50%以上[16]